Neurochemical Research

, Volume 44, Issue 9, pp 2147–2155 | Cite as

The Binding Mechanisms and Inhibitory Effect of Intravenous Anesthetics on AChE In Vitro and In Vivo: Kinetic Analysis and Molecular Docking

  • Mesut IşıkEmail author
Original Paper


Inhibitors of acetylcholinesterase (AChE), which have an important role in the prevention of excessive AChE activity and β-amyloid (Aβ) formation are widely used in the symptomatic treatment of Alzheimer's disease (AD). The inhibitory effect of anesthetic agents on AChE was determined by several approaches, including binding mechanisms, molecular docking and kinetic analysis. Inhibitory effect of intravenous anesthetics on AChE as in vitro and in vivo have been discovered. The midazolam, propofol and thiopental have shown competitive inhibition type (midazolam > propofol > thiopental) and Ki values were found to be 3.96.0 ± 0.1, 5.75 ± 0.12 and 29.65 ± 2.04 µM, respectively. The thiopental and midazolam showed inhibition effect on AChE in vitro, whereas they showed activation effect in vivo when they are combined together. The order of binding of the drugs to the active site of the 4M0E receptor was found to be midazolam > propofol > thiopental. This study on anesthetic agents that are now widely used in surgical applications, have provided a molecular basis for investigating the drug-enzyme interactions mechanism. In addition, the study is important in understanding the molecular mechanism of inhibitors that are effective in the treatment of AD.


Alzheimer’s disease AChE inhibition Anesthetic drugs Molecular docking 



The authors are grateful for the financial which provided by the Research Foundation of Atatürk University.

Compliance with Ethical Standards

Conflict of interest

The authors declare that they have no conflict of interest.


  1. 1.
    Santamaria LB, Schifilliti D, La Torre D, Fodale V (2010) Drugs of anaesthesia and cancer. Surg Oncol. Google Scholar
  2. 2.
    Kvolik S, Glavas-Obrovac L, Bares V, Karner I (2005) Effects of inhalation anesthetics halothane, sevoflurane, and isoflurane on human cell lines. Life Sci. Google Scholar
  3. 3.
    Mammoto T, Mukai M, Mammoto A et al (2002) Intravenous anesthetic, propofol inhibits invasion of cancer cells. Cancer Lett. Google Scholar
  4. 4.
    Inal M, Alatas O, Kural T, Sevin B (1994) Oxygen free radicals in erythrocytes during open heart operation. J Cardiovasc Surg 35:147–150Google Scholar
  5. 5.
    Weiss M, Buhl R, Birkhahn A et al (1994) Do barbiturates and their solutions suppress FMLP-induced neutrophil chemiluminescence? Eur J Anaesthesiol 11:371–379Google Scholar
  6. 6.
    Kelicen P, Ismailoglu UB, Erdemli O, Sahin-Erdemli I (1997) The effect of propofol and thiopentone on impairment by reactive oxygen species of endothelium-dependent relaxation in rat aortic rings. Eur J Anaesthesiol. Google Scholar
  7. 7.
    Vasileiou I, Xanthos T, Koudouna E et al (2009) Propofol: a review of its non-anaesthetic effects. Eur J Pharmacol. Google Scholar
  8. 8.
    Lee Y-M, Song BC, Yeum K-J (2015) Impact of volatile anesthetics on oxidative stress and inflammation. Biomed Res Int. Google Scholar
  9. 9.
    Calabrese V, Giordano J, Signorile A et al (2016) Major pathogenic mechanisms in vascular dementia: roles of cellular stress response and hormesis in neuroprotection. J Neurosci Res. Google Scholar
  10. 10.
    Işık M, Beydemir Ş, Yılmaz A et al (2017) Oxidative stress and mRNA expression of acetylcholinesterase in the leukocytes of ischemic patients. Biomed Pharmacother. Google Scholar
  11. 11.
    Fang J, Wu P, Yang R et al (2014) Inhibition of acetylcholinesterase by two genistein derivatives: kinetic analysis, molecular docking and molecular dynamics simulation. Acta Pharm Sin B. Google Scholar
  12. 12.
    Anand P, Singh B (2013) A review on cholinesterase inhibitors for Alzheimer’s disease. Arch Pharm Res. Google Scholar
  13. 13.
    Sabbagh MN (2009) Drug development for Alzheimer’s disease: where are we now and where are we headed? Am J Geriatr Pharmacother. Google Scholar
  14. 14.
    Citron M (2010) Alzheimer’s disease: strategies for disease modification. Nat Rev Drug Discov. Google Scholar
  15. 15.
    Chaudière J, Ferrari-Iliou R (1999) Intracellular antioxidants: From chemical to biochemical mechanisms. Food Chem Toxicol. Google Scholar
  16. 16.
    Göcer H, Akincioʇlu A, Göksu S et al (2015) Carbonic anhydrase and acetylcholinesterase inhibitory effects of carbamates and sulfamoylcarbamates. J Enzyme Inhib Med Chem. Google Scholar
  17. 17.
    Alici HA, Ekinci D, Beydemir Ş (2008) Intravenous anesthetics inhibit human paraoxonase-1 (PON1) activity in vitro and in vivo. Clin Biochem. Google Scholar
  18. 18.
    Ellman GL, Courtney DK, Andres V, Featherstone RM (1961) A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol 7:88–95CrossRefGoogle Scholar
  19. 19.
    Taslimi P, Kandemir FM, Demir Y et al (2019) The antidiabetic and anticholinergic effects of chrysin on cyclophosphamide-induced multiple organ toxicity in rats: pharmacological evaluation of some metabolic enzyme activities. J Biochem Mol Toxicol. Google Scholar
  20. 20.
    Wright DL, Plummer DT (2015) Multiple forms of acetylcholinesterase from human erythrocytes. Biochem J. Google Scholar
  21. 21.
    Yamali C, Gul HI, Ece A et al (2018) Synthesis, molecular modeling, and biological evaluation of 4-[5-aryl-3-(thiophen-2-yl)-4,5-dihydro-1H-pyrazol-1-yl] benzenesulfonamides toward acetylcholinesterase, carbonic anhydrase I and II enzymes. Chem Biol Drug Des. Google Scholar
  22. 22.
    Demir Y, Işık M, Gülçin İ, Beydemir Ş (2017) Phenolic compounds inhibit the aldose reductase enzyme from the sheep kidney. J Biochem Mol Toxicol. Google Scholar
  23. 23.
    Halgren TA, Murphy RB, Friesner RA et al (2004) Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. J Med Chem. Google Scholar
  24. 24.
    Türkeş C (2019) Investigation of potential paraoxonase-I inhibitors by kinetic and molecular docking studies: chemotherapeutic drugs. Protein Pept Lett. Google Scholar
  25. 25.
    Madhavi Sastry G, Adzhigirey M, Day T et al (2013) Protein and ligand preparation: Parameters, protocols, and influence on virtual screening enrichments. J Comput Aided Mol Des. Google Scholar
  26. 26.
    Friesner RA, Banks JL, Murphy RB et al (2004) Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J Med Chem. Google Scholar
  27. 27.
    Harder E, Damm W, Maple J et al (2016) OPLS3: a force field providing broad coverage of drug-like small molecules and proteins. J Chem Theory Comput. Google Scholar
  28. 28.
    Ansley DM, Lee JU, Godin DV et al (1998) Propofol enhances red cell antioxidant capacity in swine and humans. Can J Anaesth. Google Scholar
  29. 29.
    Hans P, Deby-Dupont G, Deby C et al (1997) Increase in antioxidant capacity of plasma during propofol anesthesia. J Neurosurg Anesthesiol. Google Scholar
  30. 30.
    Manataki AD, Tselepis AD, Glantzounis GK et al (2001) Lipid peroxidation and the use of emulsified propofol in laparoscopic surgery. Surg Endosc. Google Scholar
  31. 31.
    Stratford N, Murphy P (1998) Antioxidant activity of propofol in blood from anaesthetized patients. Eur J Anaesthesiol. Google Scholar
  32. 32.
    Yagmurdur H, Cakan T, Bayrak AK et al (2004) The effects of etomidate, thiopental, and propofol in induction on hypoperfusion-reperfusion phenomenon during laparoscopic cholecystectomy. Acta Anaesthesiol Scand. Google Scholar
  33. 33.
    Harman F, Hasturk AE, Yaman M et al (2012) Neuroprotective effects of propofol, thiopental, etomidate, and midazolam in fetal rat brain in ischemia-reperfusion model. Child’s Nerv Syst. Google Scholar
  34. 34.
    Calabrese V, Giordano J, Crupi R et al (2017) Hormesis, cellular stress response and neuroinflammation in schizophrenia: early onset versus late onset state. J Neurosci Res. Google Scholar
  35. 35.
    Runzer TD, Ansley DM, Godin DV, Chambers GK (2002) Tissue antioxidant capacity during anesthesia: propofol enhances in vivo red cell and tissue antioxidant capacity in a rat model. Anesth Analg. Google Scholar
  36. 36.
    Calabrese EJ (2019) The linear No-Threshold (LNT) dose response model: a comprehensive assessment of its historical and scientific foundations. Chem Biol Interact. Google Scholar
  37. 37.
    Nishina K, Akamatsu H, Mikawa K et al (1998) The inhibitory effects of thiopental, midazolam, and ketamine on human neutrophil functions. Anesth Analg. Google Scholar
  38. 38.
    Xue Q-S, Yu B-W, Wang Z-J, Chen H-Z (2004) Effects of ketamine, midazolam, thiopental, and propofol on brain ischemia injury in rat cerebral cortical slices. Acta Pharmacol Sin 25:115–120Google Scholar
  39. 39.
    Sánchez-Conde P, Rodríguez-López JM, Nicolás JL et al (2008) The comparative abilities of propofol and sevoflurane to modulate inflammation and oxidative stress in the kidney after aortic cross-clamping. Anesth Analg. Google Scholar
  40. 40.
    Chillemi R, Cardullo N, Greco V et al (2015) Synthesis of amphiphilic resveratrol lipoconjugates and evaluation of their anticancer activity towards neuroblastoma SH-SY5Y cell line. Eur J Med Chem. Google Scholar
  41. 41.
    Trovato Salinaro A, Pennisi M, Di Paola R et al (2018) Neuroinflammation and neurohormesis in the pathogenesis of Alzheimer’s disease and Alzheimer-linked pathologies: modulation by nutritional mushrooms. Immun Ageing. Google Scholar
  42. 42.
    Pastuszko A (1980) Action of barbiturates on activity of acetylcholinesterase from synaptosomal membranes. Neurochem Res. Google Scholar
  43. 43.
    Kakinuma Y, Furihata M, Akiyama T et al (2010) Donepezil, an acetylcholinesterase inhibitor against Alzheimer’s dementia, promotes angiogenesis in an ischemic hindlimb model. J Mol Cell Cardiol. Google Scholar
  44. 44.
    Bartolini M, Bertucci C, Cavrini V, Andrisano V (2003) β-Amyloid aggregation induced by human acetylcholinesterase: inhibition studies. Biochem Pharmacol. Google Scholar
  45. 45.
    García-Ayllón M-S (2011) Revisiting the role of acetylcholinesterase in Alzheimer’s disease: cross-talk with P-tau and β-amyloid. Front Mol Neurosci. Google Scholar
  46. 46.
    Von Bernhardi R, Alarcón R, Mezzano D et al (2005) Blood cells cholinesterase activity in early stage Alzheimer’s disease and vascular dementia. Dement Geriatr Cogn Disord. Google Scholar
  47. 47.
    Blennow K (2010) Biomarkers in Alzheimer’s disease drug development. Nat Med. Google Scholar
  48. 48.
    Sánchez JM, Demartini AF, Roca ADTL (2003) Interaction of donepezil and muscular blockers in Alzheimer’s disease. Rev Esp Anestesiol Reanim 50:97–100Google Scholar
  49. 49.
    Curatola G, Mazzanti L, Lenaz G, Pastuszko A (1979) General anesthetics inhibit erythrocyte acetylcholinesterase only when membrane-bound. Bull Mol Biol Med 4:139–146Google Scholar
  50. 50.
    Spinedi A, Pacini L, Luly P (2015) A study of the mechanism by which some amphiphilic drugs affect human erythrocyte acetylcholinesterase activity. Biochem J. Google Scholar
  51. 51.
    Cohen ML, Chan SL, Bhargava HN, Trevor AJ (1974) Inhibition of mammalian brain acetylcholinesterase by ketamine. Biochem Pharmacol. Google Scholar
  52. 52.
    Braswell LM, Kitz RJ (1977) The effect in vitro of volatile anesthetics on the activity of cholinesterases. J Neurochem. Google Scholar
  53. 53.
    Tassonyi E, Charpantier E, Muller D et al (2002) The role of nicotinic acetylcholine receptors in the mechanisms of anesthesia. Brain Res Bull. Google Scholar
  54. 54.
    Hertle I, Scheller M, Bufler J et al (1997) Interaction of midazolam with the nicotinic acetylcholine receptor of mouse myotubes. Anesth Analg. Google Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Pharmacy Services, Vocational School of Health ServicesHarran UniversityŞanlıurfaTurkey

Personalised recommendations